New research has identified the enzyme glutamate dehydrogenase 1 (GLUD1) as a new therapeutic target for Duchenne muscular dystrophy (DMD). In preclinical DMD mouse models, investigators demonstrated that inhibiting GLUD1 significantly enhances muscle strength and coordination, signaling a potential shift toward restoring muscle function rather than just managing symptoms. The groundbreaking study in The American Journal of Pathology points toward a promising and feasible pathway to treat DMD based on muscle glutamate exploitation, addressing a clinically unmet need.
This article was originally published on MedicalXpress.com
